Open Access

Kinetic spectrophotometric determination of an important pharmaceutical compound, pregabalin

  • Raafia Najam1,
  • Gh Mohd Shah1 and
  • S Muzaffar Ali Andrabi2Email author
Contributed equally
Journal of Analytical Science and Technology20134:22

DOI: 10.1186/2093-3371-4-22

Received: 1 May 2013

Accepted: 29 October 2013

Published: 2 December 2013



Pregabalin (PGB), an anticonvulsant, was studied throughout this work using spectrophotometric method.


The spectrophotometric method is based on the condensation reaction of PGB with p-dimethylaminobenzaldehyde (p DMAB) in acid medium. The condensation product showed λ max at 420 nm.


The different parameters affecting the stability of the condensation product were carefully studied and optimized. The calibration plots were constructed over the concentration range of 40 to 120 μg ml-1.


A simple, reliable, sensitive and accurate spectrophotometric method has been developed for the determination of an anticonvulsant drug, PGB. The proposed method was successfully applied to the analysis of the drug in dosage form. The high sensitivity of the proposed method allows determination of PGB in bulk and in pharmaceutical preparations.


PGB p DMAB Spectrophotometric determination Capsules


Pregabalin (PGB), (S)-3-(aminomethyl)-5-methyl hexanoic acid is an antiepileptic and structurally related to the inhibitory neurotransmitter aminobutyric acid (GABA). It is a white crystalline solid with molecular formula C8H17NO2, molecular mass of 159.23 g/mol and melting point from 190°C to 192°C. It was approved in the year 2007 for adjunctive treatment of partial seizures in adults (Tassone et al. 2007; Hamandi and Sander 2006; Barona et al. 2008) in United States and Europe, and for the treatment of neuropathic pain from post-therapeutic neuralgia and diabetic neuropathy.

The wide use of this drug has prompted many researches to develop sensitive and accurate analytical methods for its determination, especially for routine quality control in the analysis of pharmaceutical products. Several methods have been developed for the determination of the drug in pure and pharmaceutical preparations which are mostly based on chromatographic, spectrofluorimetric and spectrophotometric methods listed elsewhere (Bali and Gaur 2011). A detailed literature survey shows that few spectrophotometric methods have been developed for the determination of PGB in bulk and pharmaceutical preparation. A sensitive and selective spectrophotometric method, based on the reaction of the drug with 7-chloro-4-nitrobenzofuran, has been developed for the determination of PGB by Onal and Sagirli (2009). The relation between the absorbance of the reaction product at 460 nm and the concentration is rectilinear over the range 0.5 to 7.0 μg/ml. Gujral et al. (2009) developed a simple and sensitive method for the determination of PGB in bulk and pharmaceutical formulations. The method is based on the reaction of the drug with a mixture of potassium iodate and potassium iodide. The method is linear over the range 0.5 to 3.5 μg/ml. Onal (2009) developed three methods for the determination of PGB in pharmaceutical preparations. Two methods are based on the charge transfer complexation of the drug with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and 7,7,8,8-tetracyanoquinodimethane (TCNQ), and the third method was based on the reaction of ninhydrin with the primary amine group on the drug molecule. While the first two methods were linear over the concentration ranges of 2.0 to 30 and 1.5 to 10 μg/ml, respectively, the third method was linear over a much wider concentration range of 40 to 180 μg/ml. Two simple spectrophotometric methods for the quantitative estimation of PGB in bulk and pharmaceutical formulations were developed by Sowjanya et al. (2011). The first method is based on the condensation of PGB with 1,2-naphthaquinone-4-sulfonic acid sodium in alkaline medium, and the second method is based on the oxidation of 2,4-dinitrophenyhydrazine and the coupling of the oxidation product with the drug to give intensely coloured chromogen. The first method is linear over the concentration range of 5 to 45 μg/ml, and the second method is linear over the range of 50 to 450 μg/ml. Reddy (2013) developed a spectrophotometric method for determination of PGB in bulk and pharmaceutical dosage form. The method is based on the reaction of PGB with DDQ to form red colour charge-transfer complex. Beer's law is obeyed in the concentration range of 50 to 250 μg/ml for the method. UV-visible spectroscopy is the technique of choice for the accurate and cost-effective determination of pharmaceutical compounds especially in third world countries. Consequently, there is scope for the development of simple and accurate spectrophotometric methods for the determination of pregabalin in bulk and pharmaceutical formulations.

In this study, p-dimethylaminobenzaldehyde (p DMAB) has been used as a chromogenic agent for the determination of pregabalin. p DMAB possesses some peculiar structural features which account for its applicability in a wide range of reactions and processes. Its condensation reactions have been utilized for the spectrophotometric determination of many drugs (Adegoke and Umoh 2009; Adegoke and Nwoke 2008). An attempt has been made to develop a simple, accurate, rapid and economical method for determination of pregabalin in pure and pharmaceutical formulations. The method is based on the reaction of pregabalin with p DMAB in acidic medium. The method involves a one-step reaction, does not involve any extraction or heating steps and does not require any costly chemicals and equipment. The reaction is monitored spectrophotometrically, and the change in absorbance with time is measured at 420 nm.



A Systronics UV-visible spectrophotometer (model 118, Gujarat, India) with 1-cm matched quartz cells was used for the absorbance measurements. Shimadzu electronic balance (Kyoto, Japan) was used for weighing the samples.


All the chemicals and materials were of analytical grade and were purchased from Qualigens Fine Chemicals Pvt. Ltd. (Mumbai, India), and Deccan Fine Chemicals India Limited (Hyderabad, India). All the solutions were freshly prepared. PGB, AR grade, was purchased from Himedia Laboratories (Mumbai, India), and PGB 75 capsules (label amount 75 mg PGB/capsule) of various pharmaceutical manufactures were purchased from the market.

Preparation of the standard solutions

Stock solution of PGB (1,000 μg/ml) was prepared by dissolving 100 mg of drug in 10 ml of 0.5 M H2SO4 and diluting up to the mark by ethanol in a 100-ml calibrated flask. The stock solution was further diluted appropriately to get working concentrations. p DMAB (0.3% w/v) was made by dissolving 0.3 g in 100 ml of 0.5 M H2SO4.

General procedure

Construction of calibration curve

To a set of 10-ml volumetric flasks, appropriate aliquots of the standard working solution were transferred to obtain concentrations in the range 40 to 120 μg ml-1 of PGB. Aliquots of standard solution of pregabalin were mixed with 2 ml of 0.3% p DMAB, and the contents were diluted up to 10 ml with ethanol and time was noted. The reaction mixture was rapidly transferred into a cuvette, and absorbance at 420 nm was recorded after every 5 min against the reagent blank prepared simultaneously in the same manner without the analyte. First, absorbance was taken exactly 5 min after mixing PGB and p DMAB solutions. The procedure was repeated for different concentrations of the drug solution, with a constant concentration of p DMAB solution. All the experiments are carried out at room temperature. The regression equations of calibration graphs were calculated using the method of least squares.

Assay of capsules

An accurately weighed portion of powder from tablets purchased from open market equivalent to 100 mg of PGB was put in a 100-ml volumetric flask containing 10 ml of H2SO4 and was diluted up to the mark using ethanol. It was shaken thoroughly for about 5 to 10 min, filtered through a Whatman paper to remove insoluble matter and used to prepare 1,000 μg/ml using ethanol for dilution. An aliquot of this solution was diluted with ethanol to obtain a required concentration (40 to 120 μg/ml). Then, to a solution of particular concentration, 2 ml of 0.3% p DMAB was added and gently shaken. The contents were diluted up to 10 ml with ethanol. The nominal content of the capsules was determined using the corresponding regression equations or the calibration graphs.

Results and discussions

In an effort to develop a spectrophotometric method for quantification of pregabalin, its reaction with p DMAB in an acid medium for the generation of a chromophoric product was studied. PGB reacts instantly with p DMAB in an acid medium to give a light yellow colour (λ max at 420 nm). PGB shows a λ max at 180 nm and does not absorb in the visible region at all, while p DMAB shows λ max at 280 nm. The UV-visible spectrum of the product of the reaction between PGB and p DMAB is given in Figure 1. The probable mechanism of the reaction between p DMAB and PGB in acid medium is given in Scheme 1.
Figure 1

UV-visible spectrum of the product of PGB and p DMAB ( λ max 420 nm).
Scheme 1

Probable mechanism of the reaction between p DMAB and PGB in acid medium.

The condensation reaction requires the presence of an acid for the protonation of the carbonyl oxygen and thereby leaving the carbonyl carbon fully positively charged. The PGB then donates a lone pair of electrons to the carbon. Internal rearrangement thereafter results in the formation of condensation product, giving water and H+ as by-product. The intensity of colour decreases with time (Figure 2) and provides a basis for kinetic study. The decrease in the intensity of yellow colour and hence absorbance is perhaps due to partial decomposition of the reaction product into the reagents on standing. This was confirmed by measuring the λ max of the reaction mixture at different time intervals, viz., 5, 15, 30, 65 min, after mixing the reagents. The λ max has been found to remain unchanged at 420 nm. The rate of reaction was monitored spectrophotometrically at 420 nm at room temperature with various concentrations of the drug, while p DMAB was kept in excess and constant.
Figure 2

Variation of absorbance of drug-reagent mixture with time. (a) 40 μg/ml, (b) 60 μg/ml, (c) 80 μg/ml, (d) 100 μg/ml, and (e) 120 μg/ml.

Optimization of reaction conditions

Effect of acid concentration

The stability of the condensation product was checked with HCl, HNO3, oxalic acid and H2SO4. The best results were obtained when H2SO4 was used. After selecting H2SO4, the stability was checked with its varying concentrations. Lower acid concentrations gave low absorbance values, while absorbance declined with increasing acid concentrations beyond 0.5 M H2SO4. The best results were obtained with 0.5 M H2SO4 (Figure 3). For the sake of ease, the experiments were carried out with ≈ 500-μg/ml drug concentration.
Figure 3

Effect of acid concentration on absorbance of drug-reagent mixture.

Effect of pDMAB concentration

It was found that the reaction is dependent on the p DMAB concentration. The absorbance of the reaction solution increases as the reagent concentration increases, and the highest absorption intensity is attained at 0.3% (w/v) reagent concentration. A higher reagent concentration up to 1% has no effect on the absorption values. Further experiments were carried out using 0.3% (w/v) of the reagent. The results obtained are shown in Figure 4. The experiments were carried out with ≈ 600-μg/ml drug concentration.
Figure 4

Effect of concentration of p DMAB on absorbance of drug-reagent mixture.

Reaction rate method

A plot of the initial rate of reaction versus concentration of the drug (Figure 5) gives a straight line and serves as a calibration curve. The rate of the reaction was calculated from the variable time method (Presez-Bendito and Silva 1988; Martin and Bustamante 1993) of measurement as ΔA / Δt, where A is the absorbance, and t is the time in seconds. In the present study, ΔA / Δt was obtained by dividing the absorbance measured 300 s (5 minutes) after mixing the drug and the reagent solutions by 300 s, assuming that the absorbance of the coloured product at t = 0 is zero. The regression equation for the reaction rate-versus-concentration (μg/ml) graph is
Rate = 2.8 × 10 - 4 + 2.48 × 10 - 4 drug conc. μ g / ml , r 2 = 0.999 .
Figure 5

Calibration plot of the initial rate of reaction versus drug concentration.

A plot of log of reaction rate versus log of drug concentration gives a straight line (Figure 6) which shows that the reaction rate of the drug obeys the following equation:
Rate = K drug n ,
where K′ is the rate constant, n is the order of the reaction and the drug concentration is in mol/L.
Figure 6

Plot of log of reaction rate versus log of drug concentration (mol/l).

Taking logarithms of Equation (1),
Log rate = log K + n log drug Log Δ A / Δ t = log K + n log drug Log Δ A / Δ t = - 3.5664 + 0.98 log drug , r 2 = 0.999 .

Thus, K′ = 0.00027, and the reaction is first order (n = 0.98) with respect to drug concentration.

Fixed time method

Change in absorbance with time was followed for different concentrations of the drug. At a fixed time, which was accurately determined, the absorbance was measured. Calibration graphs of absorbance versus initial concentrations of the drug at fixed times of 5, 10, 15, 20,…, 50 min were drawn (Figure 7). The correlation coefficients of the curves were calculated. The regression equations for the calibration graphs corresponding to different fixed times are given in Table 1.
Figure 7

Calibration plots of absorbance versus drug concentration at fixed time. (a) 5 min, (b) 10 min, (c) 15 min, (d) 20 min, (e) 25 min, (f) 30 min, (g) 35 min, (h) 40 min, (i) 45 min, and (j) 50 min.

Table 1

Regression equations for the reaction rate and fixed time methods for the determination of pregabalin


Regression equation

r 2

Reaction rate method

Rate = 2.8 × 10-4+ 2.48 × 10-4 × drug concentration


Fixed time method, time (min)



A = 0.00106 + 0.00123 × drug concentration



A = -0.0032 + 0.00111 × drug concentration



A = -0.0038 + 0.00103 × drug concentration



A = 0.0052 + 7.2 × 10-4 × drug concentration



A = 0.0036 + 6.4 × 10-4 × drug concentration



A = 0.0034 + 5.6 × 10-4 × drug concentration



A = 0.003 + 4.9 × 10-4 × drug concentration



A = 0.0032 + 4.4 × 10-4 × drug concentration



A = 0.0026 + 3.8 × 10-4 × drug concentration



A = 0.0046 + 2.9 × 10-4 × drug concentration


A Absorbance.

The drug concentration is represented in μg/ml.

Validation of the proposed methods

Two different methods were tried to construct the calibration curves for the determination of the drug from the rate data, reaction rate method and fixed time method. The regression equations were calculated for every calibration curve. It is evident that in both methods, there is an excellent correlation between the analytical parameter and the concentration of the drug. The high correlation coefficients (r2) obtained for most of the calibration curves indicate high linearity in the range 40 to 120 μg/ml, and hence, these are suitable methods for the assay of the drug. The above methods were performed in the concentration range of 40 to 120 μg/ml. At higher concentrations, Beer's law is not obtained.

Precision and accuracy

The precision, accuracy and the applicability of the proposed methods were evaluated by measuring five independent samples of pregabalin in pharmaceutical preparations (tablet form) at 40, 60, 80, 100 and 120-μg/ml drug concentrations. Six replicate measurements were made for each concentration. The precision and accuracy were evaluated in terms of the standard deviation and percent recovery. The results are given in Table 2. The calculated relative standard deviations are around 2% for most of the concentrations studied (except for 40 μg/ml where it reaches up to 2.7%), indicating excellent precision of the proposed methods. The percent recovery has been between 96.04% and 102.9%, indicating a close agreement between the measured and true values. Hence, the proposed methods will be effective for the determination of pregabalin in pharmaceutical formulations. The condensation reaction between the drug and the reagent involves the primary aliphatic amine group. The absence of primary aliphatic amine group in the common excipients of the drug namely lactose monohydrate, talc, gelatin, maize starch and glucose eliminates any chances of interferences in the determination of the drug because of their inability to react with the reagent. The excellent RSD and %recovery values obtained with samples of pharmaceutical formulations confirm that there is no potential interference of these excipients on the proposed methods.
Table 2

Evaluation of accuracy and precision by the proposed method: determination of PGB in pharmaceutical preparations


Amount taken (μg/ml)

Amount a found (μg/ml)



RSD (%)

Reaction rate method






























Fixed time method, time (min)




























































































aAn average of six determinations.


The proposed methods are simple which preclude any use of harmful and costly solvents and reagents. p-Dimethylaminobenzaldehyde is a suitable reagent for the spectrophotometric determination of pregabalin. It is not only cheap and safe but also is available in any analytical laboratory with excellent shelf life. The procedure of the proposed methods is simple and time saving. No tedious procedures, extractions, heating and long standing times etc. are involved. The proposed method is sensitive, accurate and reproducible; requires simple apparatus for its performance; and consequently is suitable for routine quality control of the drug.



Authors’ Affiliations

PG Department of Chemistry, University of Kashmir
University Science Instrumentation Centre, University of Kashmir


  1. Adegoke OA, Nwoke CE: Spectrophotometric determination of hydralazine using p- dimethylaminobenzaldehyde. J Iranian Chem Soc 2008, 5: 316. 10.1007/BF03246124View ArticleGoogle Scholar
  2. Adegoke OA, Umoh OE: A new approach to the spectrophotometric determination of metronidazole and tinidazole using p-dimethylaminobenzaldehyde. Acta Pharm 2009, 59: 407–419.View ArticleGoogle Scholar
  3. Bali A, Gaur P: A novel method for spectrophotometric determination of pregabalin in pure form and in capsules. Chem Central J 2011, 5: 59. 10.1186/1752-153X-5-59View ArticleGoogle Scholar
  4. Barona R, Brunnmüllerb U, Brasserb M, Mayc M, Bindera A: Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia, Open-label, non-comparative, flexible-dose studies. Eur J Pain 2008, 12: 850. 10.1016/j.ejpain.2007.12.004View ArticleGoogle Scholar
  5. Gujral RS, Manirul Haque SK, Kumar S: A novel method for the determination of pregabalin in bulk pharmaceutical formulations and human urine samples. Afr J Pharm Pharmacol 2009, 3: 327–334.Google Scholar
  6. Hamandi K, Sander JW: Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure Eur J Epilep 2006, 15: 73. 10.1016/j.seizure.2005.11.005View ArticleGoogle Scholar
  7. Martin A, Bustamante P: Physical Pharmacy P: Physical Chemical Principles in the Pharmaceutical Sciences. 4th edition. Philadelphia PA: Lea and Febiger; 1993:287.Google Scholar
  8. Onal A: Development and Validation of Selective Spectrophotometric methods for the determination of Pregabalin in pharmaceutical preparation. Chin J Chem 2009, 27: 781–786. 10.1002/cjoc.200990130View ArticleGoogle Scholar
  9. Onal A, Sagirli O: Spectrophotometric and spectrofluorimetric methods for the determination of pregabalin in bulk and pharmaceutical preparation. Mol Bimol Spectros 2009, 72: 68–71. 10.1016/j.saa.2008.08.009View ArticleGoogle Scholar
  10. Presez-Bendito D, Silva M: Kinetic Methods in Analytical Chemistry. New York: John Wiley and Sons; 1988:44–45. Ch.11Google Scholar
  11. Reddy AJP: New spectrophotometric determination of pregabalin bulk and Pharmaceutical dosage form. J Drug Discov and Therap 2013, 1: 56–58.Google Scholar
  12. Sowjanya K, Thejaswini JC, Gurupadayya BM, Indu Priya M: Spectrophotometric determination of Pregabalin using 1, 2-Napthaquinone-4-sulfonic acid Sodium and 2, 4 dinitrophenyl hydrazine in pharmaceuticaldosage form. Der Pharmacia Lettre 2011, 3: 47–56.Google Scholar
  13. Tassone DM, Boyce E, Guyer J, Nuzum D: Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007, 29: 26. 10.1016/j.clinthera.2007.01.013View ArticleGoogle Scholar


© Najam et al.; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.